Abstract
Sixty-six patients with type 2 diabetes mellitus,who did not take acarbose for the previous four weeks,were divided into acarbose group (A group,n =34) and non acarbose group (B group,n =32).33 healthy volunteers were selected as healthy controls (C group).Acarbose was prescribed 50 mg three times per day in A group and other hypoglycemic agents apart from acarbose were taken in B group.After four weeks of intervention,interleukin (IL)-4,IL-6,and IL-10 levels were determined with ELISA.The results showed that the baseline levels of IL-4 and IL-10 in C group were significantly higher than those in A and B groups,while the baseline level of IL-6 was lower (P＜0.05).After four weeks of intervention,IL-6 level decreased more while IL-10 level increased more in group A than in group B (P＜0.01).Although IL-4 levels increased in both group A and group B,the trend was not statistically different between two groups.The results suggest that acarbose therapy leads to favorable interleukin profile in patients with type 2 diabetes. Key words: Diabetes mellitus, type 2 ; Interleukin ; Acarbose
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
